Theriva Biologics to Present Retinoblastoma Trial Data at APAO 2026
Event summary
- Theriva Biologics will present Phase 1 clinical trial data for VCN-01 in refractory retinoblastoma at APAO 2026 on February 7, 2026.
- Preclinical data will highlight synergistic antitumor activity when VCN-01 is combined with topotecan.
- VCN-01 has Orphan Drug and Rare Pediatric Disease designations for retinoblastoma treatment.
- The presentation will be delivered by Dr. Jaume Català-Mora from Sant Joan de Déu-Barcelona Children’s Hospital.
The big picture
Theriva Biologics' presentation at APAO 2026 underscores the growing interest in novel treatments for refractory retinoblastoma, a rare but devastating pediatric cancer. The focus on combination therapy with VCN-01 and topotecan highlights a strategic shift towards addressing unmet needs in difficult-to-treat vitreous seeds. The company's Orphan Drug designations position it favorably for regulatory and commercial advantages in this niche market.
What we're watching
- Regulatory Pathway
- Whether Theriva Biologics can refine and gain regulatory approval for a pivotal clinical trial design in retinoblastoma.
- Clinical Efficacy
- The pace at which VCN-01 demonstrates positive results in future trials for retinoblastoma and other indications.
- Commercial Strategy
- How Theriva Biologics will leverage Orphan Drug and Rare Pediatric Disease designations to accelerate market access.
Related topics